CA2779459A1 - Peptide compositions and methods for inhibiting herpesvirus infection - Google Patents

Peptide compositions and methods for inhibiting herpesvirus infection Download PDF

Info

Publication number
CA2779459A1
CA2779459A1 CA2779459A CA2779459A CA2779459A1 CA 2779459 A1 CA2779459 A1 CA 2779459A1 CA 2779459 A CA2779459 A CA 2779459A CA 2779459 A CA2779459 A CA 2779459A CA 2779459 A1 CA2779459 A1 CA 2779459A1
Authority
CA
Canada
Prior art keywords
seq
peptide
residues
sequence
hcmv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2779459A
Other languages
English (en)
French (fr)
Inventor
Lilia I. Melnik
Robert F. Garry
Cindy A. Morris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Original Assignee
Tulane University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University filed Critical Tulane University
Publication of CA2779459A1 publication Critical patent/CA2779459A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/045—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2779459A 2009-10-30 2010-10-29 Peptide compositions and methods for inhibiting herpesvirus infection Abandoned CA2779459A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28011209P 2009-10-30 2009-10-30
US61/280,112 2009-10-30
PCT/US2010/054743 WO2011053798A2 (en) 2009-10-30 2010-10-29 Peptide compositions and methods for inhibiting herpesvirus infection

Publications (1)

Publication Number Publication Date
CA2779459A1 true CA2779459A1 (en) 2011-05-05

Family

ID=43923008

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2779459A Abandoned CA2779459A1 (en) 2009-10-30 2010-10-29 Peptide compositions and methods for inhibiting herpesvirus infection

Country Status (6)

Country Link
US (2) US8802106B2 (https=)
EP (1) EP2493911B1 (https=)
JP (2) JP2013509432A (https=)
AU (1) AU2010313339B2 (https=)
CA (1) CA2779459A1 (https=)
WO (1) WO2011053798A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2627352B1 (en) * 2010-10-15 2017-05-10 GlaxoSmithKline Biologicals S.A. Cytomegalovirus gb antigen
GB201312133D0 (en) * 2013-07-05 2013-08-21 Univ Birmingham Immunotherapy
JP6679484B2 (ja) * 2013-12-11 2020-04-15 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド ヒトヘルペスウイルス三量体糖タンパク質Ｂ、三量体ｇＢを含むタンパク質複合体、及びワクチンとしてのそれらの使用
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3474887A1 (en) * 2016-06-27 2019-05-01 AiCuris Anti-infective Cures GmbH Hcmv entry inhibitors
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN111675752B (zh) * 2020-03-16 2023-07-07 成都奥达生物科技有限公司 一种冠状病毒膜融合抑制剂及其药物用途
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
CA3211449A1 (en) * 2021-02-24 2022-09-01 Pfizer Inc. Novel druggable regions in the human cytomegalovirus glycoprotein b polypeptide and methods of use thereof
CN115894708B (zh) * 2022-08-16 2023-10-10 青岛大学 一种人巨细胞病毒抗原表位嵌合肽及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335429C (en) * 1986-03-07 1995-05-02 Geoffrey L. Smith Processes for the production of hcmv glycoproteins, antibodies thereto and hcmv vaccines, and recombinant vectors therefor
DE68929478T2 (de) * 1988-01-29 2004-04-29 Aventis Pasteur Rekombinante CMV-Neutralisierungsproteine
US5514577A (en) 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
US5633230A (en) * 1990-10-24 1997-05-27 Allelix Biopharmaceuticals, Inc. Treatment of cytomegalovirus infection
US5831001A (en) * 1990-10-24 1998-11-03 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
GB9409962D0 (en) * 1994-05-18 1994-07-06 Smithkline Beecham Biolog Novel compounds
CA2295933A1 (en) * 1997-07-03 1999-01-14 Smithkline Beecham Corporation Compounds and methods for treating and screening viral reactivation
US20030036181A1 (en) * 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
FR2818279B1 (fr) * 2000-12-15 2005-02-25 Univ Paris Curie Peptide de la glycoproteine b de l'herpesvirus humain 7 utilisable notamment dans un test serologique elisa
AUPR593101A0 (en) * 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
DK2311848T3 (da) * 2002-12-23 2013-10-14 Vical Inc Kodon-optimerede polynukleotidbaserede vacciner mod human cytomegalovirus-infektion
US7491490B2 (en) * 2004-05-12 2009-02-17 Wisconsin Alumni Research Foundation Cytomegalovirus disintegrin-like peptides
US20090181889A1 (en) * 2006-03-08 2009-07-16 University Of Rochester Compositions and methods for detection and treatment of human herpesvirus (hhv)-6
CN101780277A (zh) * 2009-01-15 2010-07-21 鑫品生医科技股份有限公司 含衍生自细胞巨大病毒的免疫原组成物及其使用方法
EP2627352B1 (en) * 2010-10-15 2017-05-10 GlaxoSmithKline Biologicals S.A. Cytomegalovirus gb antigen

Also Published As

Publication number Publication date
US8802106B2 (en) 2014-08-12
EP2493911A4 (en) 2014-01-01
AU2010313339A1 (en) 2012-06-07
WO2011053798A2 (en) 2011-05-05
EP2493911A2 (en) 2012-09-05
JP2013509432A (ja) 2013-03-14
WO2011053798A3 (en) 2011-09-22
US9434769B2 (en) 2016-09-06
EP2493911B1 (en) 2017-10-18
JP2016128477A (ja) 2016-07-14
JP6209228B2 (ja) 2017-10-04
AU2010313339B2 (en) 2016-05-26
US20150119318A1 (en) 2015-04-30
US20130005648A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
AU2010313339B2 (en) Peptide compositions and methods for inhibiting herpesvirus infection
Heldwein et al. Entry of herpesviruses into mammalian cells
Vanarsdall et al. PDGF receptor-α does not promote HCMV entry into epithelial and endothelial cells but increased quantities stimulate entry by an abnormal pathway
Melnik et al. Peptide inhibition of human cytomegalovirus infection
Yang et al. The intracellular domain of duck plague virus glycoprotein E affects UL11 protein incorporation into viral particles
Li et al. Deleting UL49. 5 in duck plague virus causes attachment, entry and spread defects
Bahnamiri et al. Distinct roles of viral US3 and UL13 protein kinases in herpes virus simplex type 1 (HSV-1) nuclear egress
Dogrammatzis Manipulating the Social Network during Viral Infections
Streck Human cytomegalovirus utilizes ESCRT-III and extracellular vesicles to enhance virus spread
Lambert Varicella-Zoster virus ORF9p: role in viral envelopment and cell-cell fusion
Chi et al. In vitro and in vivo broad antiviral activity of peptides homologous to fusion glycoproteins of Newcastle disease virus and Marek's disease virus
Zhao TRIM5α is a poxvirus restriction factor: viral evasion strategies and a pathway to antivirals
Henderson A Cytomegalovirus Glycoprotein H-Associated Tropism and Entry (GATE) Complex Enhances Endothelial Cell Infection
Shao Characterization of Epstein-Barr virus BALF0/BALF1 proteins
Sandhu Targeted Modulation of Host Immune Proteins by Human Cytomegalovirus
KR20220007108A (ko) 헤르페스바이러스과 감염의 치료 또는 예방에 사용하기 위한 펩티드
Strahan The Role of ORF59 in coupling viral transcription and replication
Massaro Interaction of Glycoproteins H/L from human α-herpesviruses with αvβ integrins
Gao The Role of HSV-2 UL16 in Nuclear Egress of Capsids
Leiper Characterisation of mutants in the herpes simplex virus-1 ICP27 regulatory protein
Brandt MULTIPLE PEPTIDES HOMOLOGOUS TO HERPES SIMPLEX VIRUS TYPE 1 GLYCOPROTEIN B INHIBIT VIRAL INFECTION 2
Vu Mechanisms of nuclear lamina disruption and regulation of nuclear budding of herpes simplex virus type-1
Eisfeld Viral and cellular targets for the varicella-zoster virus ORF66 protein kinase
Kalu Pharmacologically-induced cellular stress and herpesvirus replication
Cochrane Characterisation of the human cytomegalovirus immunomodulatory gene UL141

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151029

FZDE Discontinued

Effective date: 20190423